TAG:
genetic test
Pathologists in China, U.S. Linked By Digital Pathology
By Robert Michel | From the Volume XIX No. 12 – August 27, 2012 Issue
CEO Summary: It is one of the first clinical collaborations of this type to be anchored by use of digital pathology. Pathologists at the medical schools of the Second Affiliated Hospital of Zhejiang University in Hangzhou, China, and the University of California Los Angeles (UCLA) are exc…
Leica, Aperio, Myriad, AMP, Hologic, Gen-Probe
By Robert Michel | From the Volume XIX No. 12 – August 27, 2012 Issue
LEICA BIOSYSTEMS TO ACQUIRE APERIO FOR THE SECOND TIME IN AS MANY YEARS, a global leader in histology systems and products has announced that it will acquire one of the leading digital pathology companies. This time it is Leica Biosystems of Nussloch, German…
Digital Pathology Enables UCLA–China Lab Connection
By Robert Michel | From the Volume XIX No. 10 – July 16, 2012 Issue
CEO SUMMARY: Digital pathology holds the promise of interconnecting pathologists around the globe in ways that advance diagnostic accuracy and improve patient outcomes. One pioneering digital pathology collaboration involves the pathology departments at the medical schools of the Universi…
Pathologists Can Offer ‘Companion Informatics’
By Joseph Burns | From the Volume XIX No. 9 – June 25, 2012 Issue
CEO SUMMARY: Community hospitals are recognizing increased interest in personalized medicine among consumers. One expert predicts that this will create opportunities for hospital labs and pathology groups to add value by offering subspecialty expertise in molecular diagnostics, genetic te…
Exome Sequencing Next “Big Thing” for Diagnosis
By Joseph Burns | From the Volume XIX No. 5 – April 2, 2012 Issue
CEO SUMMARY: For disease diagnostics, exome sequencing is not yet routine, but geneticists are getting close. Using this technology, researchers read those parts of the human genome where about 85% of disease-causing mutations reside. By looking only at the regions that encode proteins—…
Roche Offers $5.7 Billion To Acquire Illumina Inc.
By Joseph Burns | From the Volume XIX No. 2 – January 30, 2012 Issue
CEO SUMMARY: Once again, Roche is hunting for gene sequencing and gene analysis technology that can support its goal of being a world leader in gene-based therapeutics and clinical lab testing that utilizes gene tests and molecular diagnostics. Last week, Roche launched a hostile stock te…
GHSU Graduates Med Techs Using Distance Training
By Robert Michel | From the Volume XIX No. 2 – January 30, 2012 Issue
CEO SUMMARY: Many clinical labs experiencing a shortage of trained medical laboratory scientists (MLS) in their city continue to overlook how the use of distance training programs could help them attract and retain top-performers. Leaders of the clinical laboratory scientist (CLS…
2011’s Top 10 Lab Stories Point to a Busy 2012
By Robert Michel | From the Volume XIX No. 1 – January 9, 2012 Issue
CEO SUMMARY: Given the specific news stories that make up THE DARK REPORT’S list of the “Top Ten Lab Stories for 2011,” it might be said that 2011 was a rather quiet year overshadowed by anticipation of the coming reforms mandated by the Accountable Care Act of 2010. For the clinica…
Why Capitate Genetic and Molecular Test Prices?
By R. Lewis Dark | From the Volume XVIII No. 17 – December 19, 2011 Issue
HOW MANY OF YOU LIVED THROUGH THE DECADE OF THE 1990s and experienced the free fall in the prices managed care plans paid for clinical laboratory testing? In California—at the peak of this insanity—some lab companies offered full risk, capitated contracts for as low as 20¢ PMPM (per member per m…
ACLA Has its Say Regarding Molecular Dx Proposals
By Robert Michel | From the Volume XVIII No. 17 – December 19, 2011 Issue
CEO SUMMARY: It is not known how many public comments have been submitted to Palmetto GBA, the big Medicare carrier, in response to its published proposals to change how code stacked claims for genetic and molecular tests will be handled, effective February 27, 2012, for labs in Medicare …
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized